2021
Risk of Intestinal Necrosis With Sodium Polystyrene Sulfonate: A Systematic Review and Meta‐analysis
Holleck JL, Roberts AE, Marhoffer EA, Grimshaw AA, Gunderson CG. Risk of Intestinal Necrosis With Sodium Polystyrene Sulfonate: A Systematic Review and Meta‐analysis. Journal Of Hospital Medicine 2021, 16: 489-494. PMID: 34328838, DOI: 10.12788/jhm.3655.Peer-Reviewed Original ResearchConceptsSevere gastrointestinal side effectsGastrointestinal side effectsIntestinal necrosisHazard ratioSide effectsComposite outcomeOdds ratioSodium polystyrene sulfonateSystematic reviewSevere gastrointestinal adverse eventsGastrointestinal adverse eventsPooled hazard ratioRisk of biasPooled odds ratioCase-control studyPrior systematic reviewsSystematic literature searchAdverse eventsAlternative medicationsCochrane LibraryDatabase inceptionClinical trialsNecrosis rateInclusion criteriaPotential confounding
2020
Prevalence of harmful diagnostic errors in hospitalised adults: a systematic review and meta-analysis
Gunderson CG, Bilan VP, Holleck JL, Nickerson P, Cherry BM, Chui P, Bastian LA, Grimshaw AA, Rodwin BA. Prevalence of harmful diagnostic errors in hospitalised adults: a systematic review and meta-analysis. BMJ Quality & Safety 2020, 29: 1008-1018. PMID: 32269070, DOI: 10.1136/bmjqs-2019-010822.Peer-Reviewed Original ResearchConceptsAdverse eventsDiagnostic errorsPhysician reviewSystematic reviewInpatient adverse eventsRisk of biasPatient safety hazardsSystem-related factorsSystematic literature searchWeb of SciencePulmonary embolismAdult patientsCase seriesCommon diagnosisPooled rateAdult admissionsCochrane LibraryDatabase inceptionDiagnostic error rateStudy characteristicsLiterature searchPatientsCommon diseaseDiagnosisCommon being
2019
Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series
Gnanapandithan K, Kharel P, Grimshaw A, Giri S. Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series. Blood 2019, 134: 3606. DOI: 10.1182/blood-2019-132203.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsAutoimmune hemolytic anemiaPure red cell aplasiaImmune thrombocytopeniaThrombotic thrombocytopenic purpuraCase reportICI therapyIntravenous immunoglobulinHematopoietic growth factorsCheckpoint inhibitorsMost patientsAdverse eventsHemophagocytic lymphohistiocytosisSupportive treatmentCase seriesClinical presentationCommon subtypeTreatment strategiesEligibility criteriaSystematic reviewNon-small cell lung cancerOrgan systemsGrowth factorAnti-thymocyte globulinHigh-dose corticosteroidsEvaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials
Giri S, Aryal M, Yu H, Grimshaw A, Pathak R, Huntington S, Dhakal B. Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials. Blood 2019, 134: 2188. DOI: 10.1182/blood-2019-130389.Peer-Reviewed Original ResearchProgression-free survivalOverall response rateHematopoietic cell transplantFront-line treatmentAdverse eventsOverall survivalMM patientsMultiple myelomaFrontline regimensClinical trialsAdvisory CommitteeCommon grade 3Cumulative ranking (SUCRA) probabilitiesFront-line regimensHigher adverse eventsPrimary efficacy outcomeTransplant-ineligible patientsPhase III RCTsNetwork Meta-AnalysisBias assessment toolRisk of biasEvaluation of efficacyIndividual patient needsEfficacious regimenEfficacious regimens